Pacira Pharma pain drug fails late-stage trial (Reuters) - Pacira Pharmaceuticals Inc said its lead drug did not meet the main goal in a late-stage trial of reducing pain for patients undergoing a surgical procedure called posterolateral thoracotomy. Pacira said the company did not meet the main goal of reducing pain scores over 72 hours, compared with a placebo. The results are from a second late-stage study of the drug, Exparel, which is ...
Aug. 1, 2013 - Reuters via Yahoo! News
Pacira Pharmaceuticals Exparel Phase 3 trial did not meet primary endpoint Pacira Pharmaceuticals announced results from its second pivotal, Phase 3 clinical trial assessing the safety and efficacy of Exparel in intercostal nerve block for posterolateral thoracotomy. The study ...
Aug. 1, 2013 - Theflyonthewall.com via Yahoo! Finance